Table of Content

1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.3 STUDY SCOPE 46
1.3.1 MARKETS COVERED 46
1.3.2 REGIONAL SCOPE 47
1.3.3 INCLUSIONS AND EXCLUSIONS 47
1.3.4 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 49
1.5 STAKEHOLDERS 49
1.6 SUMMARY OF CHANGES 50
2 RESEARCH METHODOLOGY 51
2.1 RESEARCH DATA 51
2.1.1 SECONDARY DATA 52
2.1.2 PRIMARY DATA 52
2.2 GLOBAL MARKET ESTIMATION 53
2.2.1 MARKET ESTIMATION METHODOLOGY 53
2.2.1.1 Insights from primary experts 56
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 57
2.3 MARKET GROWTH RATE PROJECTION 58
2.4 DATA TRIANGULATION 60
2.5 RESEARCH ASSUMPTIONS 61
2.6 RESEARCH LIMITATIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 68
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET 68
4.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND
COUNTRY (2024) 69
4.3 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030) 69
4.4 CLINICAL TRIAL SERVICES MARKET, BY END USER (2024) 70
4.5 CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 70
?
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
5.2.1 DRIVERS 72
5.2.1.1 Increasing focus on patient-centric trials (DCTs) 72
5.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing 73
5.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities 74
5.2.1.4 Service flexibility offered by CROs for clinical development
(FSP, FSO, Hybrid) 75
5.2.1.5 Technological integrations 76
5.2.2 OPPORTUNITIES 76
5.2.2.1 Increased focus on pediatric clinical trials 76
5.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials 77
5.2.2.3 Growing role of real-world evidence in drug approvals 78
5.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials 79
5.2.3 CHALLENGES 80
5.2.3.1 Cybersecurity or intellectual property concerns 80
5.2.3.2 Challenge of patient retention 80
5.2.3.3 Growing market competition 81
5.3 MARKET TRENDS 81
5.3.1 IN SILICO CLINICAL TRIALS 81
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
5.5 PRICING ANALYSIS 82
5.5.1 PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE) 82
5.5.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2024 83
5.5.3 INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024 84
5.6 VALUE CHAIN ANALYSIS 84
5.7 ECOSYSTEM ANALYSIS 86
5.8 INVESTMENT AND FUNDING SCENARIO 88
5.9 TECHNOLOGY ANALYSIS 89
5.9.1 KEY TECHNOLOGIES 89
5.9.1.1 Clinical trial management system (CTMS) 89
5.9.1.2 Electronic data capture (EDC) systems 89
5.9.1.3 Randomization and trial supply management (RTSM) 90
5.9.2 COMPLEMENTARY TECHNOLOGIES 91
5.9.2.1 Telemedicine and wearable devices 91
5.9.2.2 AI and ML integration 91
5.10 KEY CONFERENCES AND EVENTS, 2025–2026 92
?
5.11 REGULATORY LANDSCAPE 93
5.11.1 REGULATORY FRAMEWORK 93
5.11.1.1 North America 93
5.11.1.2 Europe 94
5.11.1.3 Asia Pacific 94
5.11.1.4 RoW 95
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
5.12 PORTER’S FIVE FORCES ANALYSIS 103
5.12.1 THREAT OF NEW ENTRANTS 104
5.12.2 THREAT OF SUBSTITUTES 105
5.12.3 BARGAINING POWER OF SUPPLIERS 105
5.12.4 BARGAINING POWER OF BUYERS 105
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 105
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 106
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
5.13.2 BUYING CRITERIA 107
5.14 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 109
5.14.1 INTRODUCTION 109
5.14.2 MARKET POTENTIAL FOR CLINICAL TRIALS 109
5.14.3 AI USE CASES 110
5.14.4 KEY COMPANIES IMPLEMENTING AI 111
5.14.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM 111
6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE 112
6.1 INTRODUCTION 113
6.2 CLINICAL TRIAL MANAGEMENT & MONITORING 114
6.2.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH 114
6.3 LABORATORY SERVICES 117
6.3.1 ANALYTICAL TESTING SERVICES 121
6.3.1.1 Increasing demand for analytical testing for drug development to drive market 121
6.3.2 BIOANALYTICAL TESTING SERVICES 124
6.3.2.1 Rising focus on biologics in advanced therapies to drive market 124
6.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES 127
6.4.1 BIOSTATISTICS 131
6.4.1.1 Integration of real-world data (RWD) into statistical analysis to support market growth 131
6.4.2 OTHER DATA MANAGEMENT SERVICES 134
?
6.5 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES 137
6.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET 137
6.6 CONSULTING 140
6.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET 140
6.7 PATIENT RECRUITMENT & RETENTION 143
6.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH 143
6.8 MEDICAL WRITING 145
6.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET 145
6.9 SAFETY & PHARMACOVIGILANCE 148
6.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH 148
6.10 OTHER SERVICE TYPES 151
7 CLINICAL TRIAL SERVICES MARKET, BY PHASE 154
7.1 INTRODUCTION 155
7.2 PHASE III 156
7.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING 156
7.3 PHASE II 159
7.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS 159
7.4 PHASE I 162
7.4.1 DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH 162
7.5 PHASE IV 166
7.5.1 SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH 166
8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY 169
8.1 INTRODUCTION 170
8.2 SMALL MOLECULES 170
8.2.1 EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH 170
8.3 BIOLOGICS 174
8.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND 174
8.4 MEDICAL DEVICES & IVD 177
8.4.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND 177
9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 180
9.1 INTRODUCTION 181
9.2 ONCOLOGY 182
9.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET 182
9.3 NEUROLOGY 187
9.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET 187
9.4 RESPIRATORY DISORDERS 190
9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 190
9.5 METABOLIC DISORDERS/ENDOCRINOLOGY 193
9.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH 193
9.6 CARDIOVASCULAR SYSTEM DISORDERS 197
9.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET 197
9.7 DERMATOLOGY 200
9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH 200
9.8 GASTROINTESTINAL DISEASES 203
9.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET 203
9.9 IMMUNOLOGICAL DISORDERS 206
9.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS
TO FUEL MARKET GROWTH 206
9.10 INFECTIOUS DISEASES 209
9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET 209
9.11 PSYCHIATRY 212
9.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS
TO SUPPORT MARKET GROWTH 212
9.12 OPHTHALMOLOGY 215
9.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS
TO SUPPORT SEGMENT GROWTH 215
9.13 HEMATOLOGY 218
9.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 218
9.14 GENITOURINARY & WOMEN’S HEALTH 221
9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN
TO PROPEL MARKET 221
9.15 OTHER THERAPEUTIC AREAS 224
10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL 228
10.1 INTRODUCTION 229
10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 229
10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES
TO DRIVE MARKET 229
10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 233
10.3.1 GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 233
?
10.4 HYBRID MODEL 236
10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO
SUPPORT MARKET GROWTH 236
11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN 239
11.1 INTRODUCTION 240
11.2 INTERVENTIONAL 240
11.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET 240
11.3 OBSERVATIONAL 244
11.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH 244
12 CLINICAL TRIAL SERVICES MARKET, BY END USER 247
12.1 INTRODUCTION 248
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 248
12.2.1 INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 248
12.3 MEDICAL DEVICE COMPANIES 253
12.3.1 RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS
BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET 253
12.4 ACADEMIC INSTITUTES 256
12.4.1 RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA
TO DRIVE MARKET 256
13 CLINICAL TRIAL SERVICES MARKET, BY REGION 259
13.1 INTRODUCTION 260
13.2 NORTH AMERICA 260
13.2.1 US 266
13.2.1.1 Presence of well-established CROs to drive market 266
13.2.2 CANADA 271
13.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market 271
13.3 EUROPE 276
13.3.1 GERMANY 281
13.3.1.1 Growing R&D spending and favorable government policies to propel market 281
13.3.2 UK 286
13.3.2.1 Rising collaborations and improved policies to support market 286
13.3.3 FRANCE 291
13.3.3.1 Government-led support for effective drug research to drive market 291
13.3.4 ITALY 296
13.3.4.1 Government-led focus on improving clinical trial regulations to drive market 296
13.3.5 SPAIN 300
13.3.5.1 Rising R&D expenditure to boost market growth 300
13.3.6 REST OF EUROPE 304
13.4 ASIA PACIFIC 309
13.4.1 CHINA 315
13.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market 315
13.4.2 INDIA 320
13.4.2.1 Cost-efficient and innovation-driven approach to propel market 320
13.4.3 JAPAN 325
13.4.3.1 Decline in number of clinical trials to limit market 325
13.4.4 AUSTRALIA 330
13.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market 330
13.4.5 SOUTH KOREA 335
13.4.5.1 Favorable government initiatives for drug development to drive market 335
13.4.6 REST OF ASIA PACIFIC 340
13.5 LATIN AMERICA 344
13.5.1 BRAZIL 348
13.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market 348
13.5.2 MEXICO 353
13.5.2.1 Increasing investments in pharma R&D to drive market 353
13.5.3 REST OF LATIN AMERICA 356
13.6 MIDDLE EAST 361
13.6.1 GCC COUNTRIES 365
13.6.1.1 Saudi Arabia 369
13.6.1.1.1 Increase in collaborations to drive market 369
13.6.1.2 UAE 374
13.6.1.2.1 Growing clinical research activities to drive market 374
13.6.1.3 Rest of GCC countries 377
13.6.2 REST OF MIDDLE EAST 382
13.6.3 AFRICA 386
13.6.3.1 Expanding pharmaceutical industry to support market growth 386
14 COMPETITIVE LANDSCAPE 390
14.1 OVERVIEW 390
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 390
14.3 REVENUE ANALYSIS 393
14.4 MARKET SHARE ANALYSIS, 2024 394
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 396
?
14.5.1 STARS 396
14.5.2 EMERGING LEADERS 396
14.5.3 PERVASIVE PLAYERS 397
14.5.4 PARTICIPANTS 397
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 398
14.5.5.1 Company footprint 398
14.5.5.2 Region footprint 399
14.5.5.3 Service type footprint 400
14.5.5.4 Phase footprint 401
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 402
14.6.1 PROGRESSIVE COMPANIES 402
14.6.2 RESPONSIVE COMPANIES 402
14.6.3 DYNAMIC COMPANIES 402
14.6.4 STARTING BLOCKS 403
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 404
14.6.5.1 Detailed list of key startups/SMEs 404
14.6.5.2 Competitive benchmarking of startups/SMEs 405
14.7 COMPANY VALUATION AND FINANCIAL METRICS 406
14.8 BRAND/SERVICE COMPARISON 407
14.9 COMPETITIVE SCENARIO 408
14.9.1 SERVICE LAUNCHES 408
14.9.2 DEALS 409
14.9.3 EXPANSIONS 410
15 COMPANY PROFILES 411
15.1 KEY PLAYERS 411
15.1.1 IQVIA INC. 411
15.1.1.1 Business overview 411
15.1.1.2 Services offered 412
15.1.1.3 Recent developments 414
15.1.1.3.1 Service launches 414
15.1.1.3.2 Deals 414
15.1.1.3.3 Expansions 416
15.1.1.4 MnM view 417
15.1.1.4.1 Right to win 417
15.1.1.4.2 Strategic choices 417
15.1.1.4.3 Weaknesses and competitive threats 417
15.1.2 ICON PLC 418
15.1.2.1 Business overview 418
15.1.2.2 Services offered 419
15.1.2.3 Recent developments 426
15.1.2.3.1 Service launches 426
15.1.2.3.2 Deals 426
15.1.2.4 MnM view 427
15.1.2.4.1 Right to win 427
15.1.2.4.2 Strategic choices 427
15.1.2.4.3 Weaknesses and competitive threats 427
15.1.3 THERMO FISHER SCIENTIFIC INC. 428
15.1.3.1 Business overview 428
15.1.3.2 Services offered 429
15.1.3.3 Recent developments 435
15.1.3.3.1 Service launches 435
15.1.3.3.2 Deals 435
15.1.3.3.3 Expansions 437
15.1.3.4 MnM view 438
15.1.3.4.1 Right to win 438
15.1.3.4.2 Strategic choices 438
15.1.3.4.3 Weaknesses and competitive threats 438
15.1.4 FORTREA 439
15.1.4.1 Business overview 439
15.1.4.2 Services offered 440
15.1.4.3 Recent developments 444
15.1.4.3.1 Service launches 444
15.1.4.3.2 Deals 444
15.1.4.3.3 Expansions 445
15.1.4.4 MnM view 445
15.1.4.4.1 Right to win 445
15.1.4.4.2 Strategic choices 445
15.1.4.4.3 Weaknesses and competitive threats 445
15.1.5 SYNEOS HEALTH 446
15.1.5.1 Business overview 446
15.1.5.2 Services offered 447
15.1.5.3 Recent developments 448
15.1.5.3.1 Service launches 448
15.1.5.3.2 Deals 448
15.1.5.4 MnM view 451
15.1.5.4.1 Right to win 451
15.1.5.4.2 Strategic choices 451
15.1.5.4.3 Weaknesses and competitive threats 452
15.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 453
15.1.6.1 Business overview 453
15.1.6.2 Services offered 455
15.1.6.3 Recent developments 456
15.1.6.3.1 Service launches 456
15.1.6.3.2 Deals 456
15.1.6.3.3 Expansions 457
15.1.6.4 MnM view 458
15.1.6.4.1 Right to win 458
15.1.6.4.2 Strategic choices 458
15.1.6.4.3 Weaknesses and competitive threats 458
15.1.7 MEDPACE 459
15.1.7.1 Business overview 459
15.1.7.2 Services offered 460
15.1.8 WUXI APPTEC 463
15.1.8.1 Business overview 463
15.1.8.2 Services offered 464
15.1.8.3 Recent developments 467
15.1.8.3.1 Deals 467
15.1.9 FRONTAGE LABS 468
15.1.9.1 Business overview 468
15.1.9.2 Services offered 469
15.1.9.3 Recent developments 470
15.1.9.3.1 Deals 470
15.1.9.3.2 Expansions 471
15.1.10 PHARMARON 472
15.1.10.1 Business overview 472
15.1.10.2 Services offered 474
15.1.11 TIGERMED 475
15.1.11.1 Business overview 475
15.1.11.2 Services offered 476
15.1.11.3 Recent developments 478
15.1.11.3.1 Service approvals 478
15.1.11.3.2 Deals 479
15.1.12 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA 480
15.1.12.1 Business overview 480
15.1.12.2 Services offered 482
15.1.13 EUROFINS SCIENTIFIC 483
15.1.13.1 Business overview 483
15.1.13.2 Services offered 485
15.1.14 LINICAL 486
15.1.14.1 Business overview 486
15.1.14.2 Services offered 488
15.1.14.3 Recent developments 488
15.1.14.3.1 Deals 488
15.1.14.3.2 Expansions 489
?
15.1.15 PAREXEL INTERNATIONAL CORPORATION 490
15.1.15.1 Business overview 490
15.1.15.2 Services offered 491
15.1.15.3 Recent developments 492
15.1.15.3.1 Service launches 492
15.1.15.3.2 Deals 492
15.1.15.3.3 Expansions 494
15.2 OTHER PLAYERS 495
15.2.1 WORLDWIDE CLINICAL TRIALS 495
15.2.2 PROPHARMA 497
15.2.3 NOVOTECH 498
15.2.4 PSI 501
15.2.5 ALLUCENT 502
15.2.6 PREMIER RESEARCH 503
15.2.7 CAIDYA 504
15.2.8 ERGOMED GROUP 505
15.2.9 CLARIO 507
15.2.10 PRECISION MEDICINE GROUP, LLC. 508
15.2.11 ADVANCED CLINICAL 509
15.2.12 EPS HOLDINGS, INC. 510
15.2.13 GUIRES INC. (PEPGRA) 511
15.2.14 KCR S.A. 512
16 APPENDIX 513
16.1 DISCUSSION GUIDE 513
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 518
16.3 CUSTOMIZATION OPTIONS 520
16.4 RELATED REPORTS 520
16.5 AUTHOR DETAILS 521



List of Figures

FIGURE 1 CLINICAL TRIAL SERVICES MARKET: SEGMENTATION 46
FIGURE 2 CLINICAL TRIAL SERVICES MARKET: REGIONAL SCOPE 47
FIGURE 3 RESEARCH DESIGN 51
FIGURE 4 CLINICAL TRIAL SERVICES MARKET: BREAKDOWN OF PRIMARIES 53
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 55
FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA, INC.: REVENUE SHARE ANALYSIS (2024) 55
FIGURE 7 CLINICAL TRIAL SERVICES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 54
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 56
FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 57
FIGURE 10 CLINICAL TRIAL SERVICES MARKET: CAGR PROJECTIONS 58
FIGURE 11 DATA TRIANGULATION METHODOLOGY 60
FIGURE 12 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE 2025 VS. 2030 (USD MILLION) 63
FIGURE 13 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 2025 VS. 2030 (USD MILLION) 64
FIGURE 14 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024 (USD MILLION) 65
FIGURE 15 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024 (USD MILLION) 65
FIGURE 16 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 66
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL TRIAL SERVICES MARKET DURING FORECAST PERIOD 67
FIGURE 18 GROWING DEMAND FOR PEDIATRIC CLINICAL TRIALS FOR VARIOUS MARKETED DRUGS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS 68
FIGURE 19 SMALL MOLECULES SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN CLINICAL TRIAL SERVICES MARKET IN 2024 69
FIGURE 20 CLINICAL TRIAL MANAGEMENT & MONITORING SEGMENT DOMINATED
MARKET IN 2030 69
FIGURE 21 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT HELD LARGEST SHARE OF CLINICAL TRIAL SERVICES MARKET IN 2024 70
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 70
FIGURE 23 DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CLINICAL
TRIAL SERVICES MARKET 71
FIGURE 24 R&D SPEND OF LARGE PHARMACEUTICAL COMPANIES 2014–2023 (USD BILLION) 74
FIGURE 25 BIOSIMILAR APPROVALS IN US, 2015–2024 75
FIGURE 26 NUMBER OF CLINICAL TRIALS FOR VARIOUS MODALITIES 79
FIGURE 27 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 82
FIGURE 28 CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 30 CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 104
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY END USER 106
FIGURE 32 KEY BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER 107
FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021–2024 155
FIGURE 34 PHASE III CLINICAL TRIALS, 2014–2024 156
FIGURE 35 PHASE II CLINICAL TRIALS, 2014–2024 159
FIGURE 36 PHASE I CLINICAL TRIALS, 2014–2024 163
FIGURE 37 NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS, 2012–2024 (THOUSAND) 183
FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 194
FIGURE 39 GLOBAL R&D PIPELINE, 2015–2024 249
FIGURE 40 R&D SPENDING BY LARGE PHARMA COMPANIES, 2015–2023 (USD BILLION) 249
FIGURE 41 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET SNAPSHOT 261
FIGURE 42 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET SNAPSHOT 310
FIGURE 43 CLINICAL TRIALS IN JAPAN, 1999–2024 325
FIGURE 44 CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS 2022–2024 (USD MILLION) 393
FIGURE 45 CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS, 2024 394
FIGURE 46 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 397
FIGURE 47 CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT 398
FIGURE 48 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 403
FIGURE 49 CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 406
FIGURE 50 CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2024 406
FIGURE 51 CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON 407
FIGURE 52 IQVIA INC.: COMPANY SNAPSHOT (2024) 412
FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2023) 419
FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 429
FIGURE 55 FORTREA: COMPANY SNAPSHOT (2023) 440
FIGURE 56 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2023) 454
FIGURE 57 MEDPACE: COMPANY SNAPSHOT (2024) 460
FIGURE 58 WUXI APPTEC: COMPANY SNAPSHOT (2023) 464
FIGURE 59 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 469
FIGURE 60 PHARMARON: COMPANY SNAPSHOT (2023) 473
FIGURE 61 TIGERMED: COMPANY SNAPSHOT (2023) 476
FIGURE 62 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2023) 481
FIGURE 63 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 484
FIGURE 64 LINICAL: COMPANY SNAPSHOT (2023) 487

List of Tables

TABLE 1 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 59
TABLE 2 RISK ASSESSMENT 62
TABLE 3 CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 72
TABLE 4 INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES BY PHASE, 2024 (USD) 83
TABLE 5 INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES, BY THERAPEUTIC AREA, 2024 (USD) 84
TABLE 6 CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 87
TABLE 7 CLINICAL TRIAL SERVICES MARKET: KEY CONFERENCES AND EVENTS 2025–2026 92
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 96
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 97
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 98
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 13 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 100
TABLE 14 CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 103
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES FOR END USER 106
TABLE 16 BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER 108
TABLE 17 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 113
TABLE 18 CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 19 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 20 EUROPE: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 21 ASIA PACIFIC: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 22 LATIN AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 23 MIDDLE EAST: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 24 GCC COUNTRIES: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 25 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 118
TABLE 26 LABORATORY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 27 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 119
TABLE 28 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 119
TABLE 29 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 119
TABLE 30 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 120
TABLE 31 MIDDLE EAST: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 120
TABLE 32 GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 120
TABLE 33 LABORATORY SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 121
TABLE 34 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 122
TABLE 35 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 122
TABLE 36 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 122
TABLE 37 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 123
TABLE 38 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 123
TABLE 39 MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 123
TABLE 40 GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 124
TABLE 41 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 125
TABLE 42 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 43 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 125
TABLE 44 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 126
TABLE 45 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 46 MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 126
TABLE 47 GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 48 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 127
TABLE 49 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 129
TABLE 50 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 51 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 52 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 53 LATIN AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 54 MIDDLE EAST: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 55 GCC COUNTRIES: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 56 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY SERVICE TYPE 2023–2030 (USD MILLION) 131
TABLE 57 CLINICAL TRIAL DATA MANAGEMENT SERVICES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 58 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 59 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 60 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 61 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 62 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 63 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 64 OTHER DATA MANAGEMENT SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 135
TABLE 65 NORTH AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 66 EUROPE: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 135
TABLE 67 ASIA PACIFIC: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 68 LATIN AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 69 MIDDLE EAST: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 70 GCC COUNTRIES: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 71 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 138
TABLE 72 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 73 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 74 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 75 LATIN AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 76 MIDDLE EAST: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 77 GCC COUNTRIES: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 78 CONSULTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 79 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 141
TABLE 80 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 141
TABLE 81 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 141
TABLE 82 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 142
TABLE 83 MIDDLE EAST: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 142
TABLE 84 GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 142
TABLE 85 PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 143
TABLE 86 NORTH AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 87 EUROPE: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 88 ASIA PACIFIC: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION), BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 89 LATIN AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 90 MIDDLE EAST: PATIENT RECRUITMENT & RETENTION SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 91 GCC COUNTRIES: PATIENT RECRUITMENT & RETENTION SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 92 MEDICAL WRITING SERVICE MARKET, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 93 NORTH AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 146
TABLE 94 EUROPE: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 146
TABLE 95 ASIA PACIFIC: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 147
TABLE 96 LATIN AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 147
TABLE 97 MIDDLE EAST: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 147
TABLE 98 GCC COUNTRIES: MEDICAL WRITING SERVICE MARKET, BY COUNTRY 2023–2030 (USD MILLION) 148
TABLE 99 SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 149
TABLE 100 NORTH AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 101 EUROPE: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 102 ASIA PACIFIC: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 103 LATIN AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 104 MIDDLE EAST: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 105 GCC COUNTRIES: SAFETY & PHARMACOVIGILANCE SERVICES MARKET BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 106 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 151
TABLE 107 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 152
TABLE 108 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 152
TABLE 109 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 152
TABLE 110 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LATIN AMERICA BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 111 MIDDLE EAST: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 153
TABLE 112 GCC COUNTRIES: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 2023–2030 (USD MILLION) 153
TABLE 113 CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 155
TABLE 114 CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY REGION 2023–2030 (USD MILLION) 157
TABLE 115 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 116 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY 2023–2030 (USD MILLION) 157
TABLE 117 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 118 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 119 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 120 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 121 CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY REGION 2023–2030 (USD MILLION) 160
TABLE 122 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 123 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY 2023–2030 (USD MILLION) 161
TABLE 124 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 125 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 126 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 127 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 128 CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY REGION 2023–2030 (USD MILLION) 163
TABLE 129 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 130 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 131 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 132 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 133 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 134 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 135 CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY REGION 2023–2030 (USD MILLION) 166
TABLE 136 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 137 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY 2023–2030 (USD MILLION) 167
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 139 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 140 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 141 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 142 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 170
TABLE 143 CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION 2023–2030 (USD MILLION) 171
TABLE 144 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES BY REGION, 2023–2030 (USD MILLION) 171
TABLE 145 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 146 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES BY REGION, 2023–2030 (USD MILLION) 172
TABLE 147 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES BY REGION, 2023–2030 (USD MILLION) 173
TABLE 148 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES BY REGION, 2023–2030 (USD MILLION) 173
TABLE 149 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES BY REGION, 2023–2030 (USD MILLION) 173
TABLE 150 CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION 2023–2030 (USD MILLION) 174
TABLE 151 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 152 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION 2023–2030 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 154 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 155 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 156 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 157 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY REGION, 2023–2030 (USD MILLION) 177
TABLE 158 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 159 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 160 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 161 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES &
IVD, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 162 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES &
IVD, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 163 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 164 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 2023–2030 (USD MILLION) 181
TABLE 165 NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 182
TABLE 166 CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY REGION 2023–2030 (USD MILLION) 184
TABLE 167 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 168 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 169 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 170 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 171 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 172 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 173 CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY REGION 2023–2030 (USD MILLION) 188
TABLE 174 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 175 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 176 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 177 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 178 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 179 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 180 CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 191
TABLE 181 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 182 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 183 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 184 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 185 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 186 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 187 CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 195
TABLE 188 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 189 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 190 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 191 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 192 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 193 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 194 CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 198
TABLE 195 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 196 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 197 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 198 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 199 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 200 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 201 CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY REGION 2023–2030 (USD MILLION) 201
TABLE 202 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 203 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 204 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 205 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 206 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 207 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 208 CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES BY REGION, 2023–2030 (USD MILLION) 204
TABLE 209 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 210 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 211 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 212 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 213 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 214 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 215 CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 207
TABLE 216 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 217 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 218 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 219 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 220 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 221 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 222 CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 210
TABLE 223 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 224 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 225 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 226 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 227 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 228 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 229 CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY REGION 2023–2030 (USD MILLION) 213
TABLE 230 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 231 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 232 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 233 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 234 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 235 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 236 CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION 2023–2030 (USD MILLION) 216
TABLE 237 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 238 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 239 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 240 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 241 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 242 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 243 CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY REGION 2023–2030 (USD MILLION) 219
TABLE 244 NORTH AMERICA: CLINI